Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine

Gajanan Sapkal; Rajni Kant; Gaurav Dwivedi; Rima R Sahay; Pragya D Yadav; Gururaj R Deshpande; Rajeev Singh; Dimpal A Nyayanit; Deepak Y Patil; Anita M Shete-Aich; Kamran Zaman; Anil K Chaudhari; Nivedita Gupta; Samiran Panda; Priya Abraham; Balram Bhargava

doi:10.1093/jtm/taac033

Immune responses against different variants of SARS-CoV-2 including Omicron following 6 months of administration of heterologous prime-boost COVID-19 vaccine

J Travel Med. 2022 May 31;29(3):taac033. doi: 10.1093/jtm/taac033.

Authors

Gajanan Sapkal¹, Rajni Kant², Gaurav Dwivedi², Rima R Sahay¹, Pragya D Yadav¹, Gururaj R Deshpande¹, Rajeev Singh², Dimpal A Nyayanit¹, Deepak Y Patil¹, Anita M Shete-Aich¹, Kamran Zaman², Anil K Chaudhari³, Nivedita Gupta⁴, Samiran Panda⁴, Priya Abraham¹, Balram Bhargava⁴

Affiliations

¹ Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India.
² Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India.
³ Chief Medical Officer, Community Health Centre, Siddarthnagar, Uttar Pradesh, 272207, India.
⁴ Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India.

Abstract

Comparative analysis at one- and six-months post-vaccination showed modest reduction in S1-RBD IgG antibody and NAb titers against B.1, Alpha, Beta and Delta variants in heterologous and homologous vaccine recipients groups. However, significant reduction in NAb titers against Omicron in vaccinees’ sera post-six months underlines need for cautious prospective follow-up.

Keywords: Covaxin; Covishield; Omicron; SARS-CoV-2; heterologous vaccination; neutralization.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

COVID-19 Vaccines*
COVID-19* / prevention & control
Humans
Immunity
Immunization, Secondary
SARS-CoV-2

Substances

COVID-19 Vaccines